BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19887279)

  • 1. [Indications and clinical use of sugammadex].
    Debaene B; Meistelman C
    Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S57-63. PubMed ID: 19887279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sugammadex: something new to improve patient safety or simply a gadget?].
    Plaud B
    Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S64-9. PubMed ID: 19887280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacology of sugammadex].
    Meistelman C; Fuchs-Buder T
    Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S51-6. PubMed ID: 19887278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sugammadex: a new approach to muscle relaxation and its reversal].
    Duvaldestin P
    Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S39-40. PubMed ID: 19887275
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sugammadex, a novel drug for neuromuscular blockade reversal].
    Fernández Meré LA; Alvarez-Blanco M
    Rev Esp Anestesiol Reanim; 2010 Feb; 57(2):95-102. PubMed ID: 20337001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.
    Hristovska AM; Duch P; Allingstrup M; Afshari A
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012763. PubMed ID: 28806470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to reversal of neuromuscular blockade.
    Della Rocca G; Pompei L
    Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new approach to anesthesia management in myasthenia gravis: reversal of neuromuscular blockade by sugammadex.
    de Boer HD; van Egmond J; Driessen JJ; Booij LH
    Rev Esp Anestesiol Reanim; 2010 Mar; 57(3):181-4. PubMed ID: 20422852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
    Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
    Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
    Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
    J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
    Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia?
    Meistelman C; Donati F
    Curr Opin Anaesthesiol; 2016 Aug; 29(4):462-7. PubMed ID: 27168088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Carron M; Zarantonello F; Tellaroli P; Ori C
    J Clin Anesth; 2016 Dec; 35():1-12. PubMed ID: 27871504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007362. PubMed ID: 19821409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The concept behind sugammadex.
    Epemolu O; Bom A
    Rev Esp Anestesiol Reanim; 2014 May; 61(5):272-6. PubMed ID: 24636599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
    Suy K; Morias K; Cammu G; Hans P; van Duijnhoven WG; Heeringa M; Demeyer I
    Anesthesiology; 2007 Feb; 106(2):283-8. PubMed ID: 17264722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Kotake Y; Ochiai R; Suzuki T; Ogawa S; Takagi S; Ozaki M; Nakatsuka I; Takeda J
    Anesth Analg; 2013 Aug; 117(2):345-51. PubMed ID: 23757472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
    Mosing M; Auer U; West E; Jones RS; Hunter JM
    Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children.
    Ammar AS; Mahmoud KM; Kasemy ZA
    Acta Anaesthesiol Scand; 2017 Apr; 61(4):374-380. PubMed ID: 28185260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.